Aberrant activation of the PI3K/AKT pathway is a common feature of various cancers, including breast, lung, and colorectal cancers (80, 82).SPC25’s involvement in this pathway has been well-documented, with studies showing that SPC25 promotes PI3K/AKT activation in tumor cells, contributing to enhanced cell survival and resistance to apoptosis (36, 37, 53) (Figure 2). Here, SPC25 is linked to neoplasm.